Another pharmaceutical manufacturer has announced that it is beefing up quality control management after running afoul of FDA inspectors. AMRI ($AMRI) has named Tom McGrath as director of quality for aseptic services at its Burlington, MA, facility, which last year was cited in an FDA warning letter. A string of companies including Johnson & Johnson ($JNJ), Novartis ($NVS) and Hospira ($HSP) have recently named new leaders ranging from the plant level to the executive suite, whose focus, at least in part, will be on improving GMP in plants. Release | Story